Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Lipid Absorption

Lipid Absorption

Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of Long-Term Use of Sodium-Glucose Co-Transporter-2 Inhibitors on Proteinuria and Renal Function in Patients with Type 2 Diabetes Mellitus without Chronic Kidney Disease during the COVID-19 Pandemic.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia·2025

Same author

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus.

Medicina (Kaunas, Lithuania)·2023

Same author

The role of asymmetric dimethylarginine in endothelial dysfunction and abnormal nitric oxide metabolism in systemic sclerosis: results from a pilot study.

Clinical rheumatology·2022

Same author

Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction.

Nefrologia·2022

Same author

Right ventricular performance in patients with heart failure with mildly reduced ejection fraction: the forgotten ventricle.

The international journal of cardiovascular imaging·2022

Same author

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study.

Medicina (Kaunas, Lithuania)·2022

Search research articles

Related Experiment Video

Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Ezetimibe therapy for dyslipidemia: an update.

Niki Katsiki¹, Eleni Theocharidou, Asterios Karagiannis

¹Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital,Thessaloniki, Greece.

Current Pharmaceutical Design

|January 16, 2013

Summary

Ezetimibe effectively lowers cholesterol and may offer cardiovascular benefits through anti-inflammatory effects. Clinical trial results are mixed, but ongoing studies like IMPROVE-IT aim to clarify its impact on cardiovascular disease events.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

Cardiology
Pharmacology
Metabolic Diseases

Background:

Ezetimibe inhibits intestinal cholesterol absorption, reducing LDL-C, TG, and apo B, while increasing HDL-C.
Beyond lipid-lowering, ezetimibe exhibits potential anti-inflammatory, anti-atherogenic, and antioxidant properties.
Clinical trial outcomes for ezetimibe have been controversial, with some showing benefits and others negative results.

Purpose of the Study:

To review current clinical trial data on ezetimibe.
To summarize ezetimibe's potential pleiotropic effects.
To discuss ezetimibe's use in high-risk patient populations and clinical practice.

Main Methods:

Review of up-to-date clinical trials involving ezetimibe.
Analysis of studies on ezetimibe's pleiotropic effects.
Discussion of ezetimibe's administration in specific patient groups.

Main Results:

Ezetimibe demonstrates significant lipid-lowering effects.
Potential pleiotropic effects like anti-inflammatory actions may contribute to reduced cardiovascular disease (CVD) risk.
Controversial trial outcomes necessitate further investigation, such as the IMPROVE-IT trial.

Conclusions:

Ezetimibe is a valuable agent for lipid management with potential additional cardiovascular benefits.
Further research, including ongoing trials, is crucial to fully elucidate ezetimibe's role in CVD prevention.
Ezetimibe's use in monotherapy or combination therapy warrants consideration in high-risk patients.